home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3012.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 3012
DOCN M94A3012
TI Reasons for significant disruptions in the planned therapy of
AIDS-related Kaposi's sarcoma.
DT 9412
AU Toi M; Caven G; Gilden J; Myers AM; UCHSC-Denver General Hospital.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):173 (abstract no. PB0117). Unique
Identifier : AIDSLINE ICA10/94369563
AB OBJECTIVE: To determine the frequency and causes for any significant
disruption in planned treatment for AIDS-related Kaposi's Sarcoma (KS).
METHODS: The care of the last 50 consecutive patients treated for
AIDS-related KS from 1990 through 1993 was reviewed. A significant
disruption in therapy was defined to be any delay in a scheduled cycle
of chemotherapy beyond 2 weeks or repeated delays of at least 1 week. In
addition, it was noted if the treatment for KS was discontinued due to
the development of another AIDS-related illness. RESULTS: As of this
writing, 43 of the 50 patients have died and 7 are alive. All patients
are male. Thirty-eight had cutaneous manifestations of KS, 15 of whom
had other sites involved as well, i.e., the GI tract, oral mucosa, lymph
nodes, and the lungs. The remaining 12 had extracutaneous involvement
only. The mean survival of all patients from the diagnosis of KS was 506
days. Several chemotherapy regimens were used in treatment. These
regimens were: Bleomycin alone, Bleomycin in combination with
vincristine, and, Adriamycin, Bleomycin, and vincristine (ABV). 35
patients (70%) had significant delays in or discontinuation of their
planned therapy. The most common reasons for therapy disruption, were,
either alone or in combination: severe neutropenia, 10 cases; CMV
retinitis, 9 cases; PCP, 7 cases; fungal infections, 6 cases; and MAI, 6
cases. Other less common causes were: AIDS dementia, CNS lymphoma, CNS
Toxoplasmosis, AIDS wasting syndrome, neurological disorders, and
Mycobacterium tuberculosis. DISCUSSION AND CONCLUSION: The treatment of
AIDS-related KS was frequently disrupted as a result of either the
development of treatment-related toxicity or the emergence of other
AIDS-related illnesses with consequent compromise of the successful
management of the KS.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY
Antineoplastic Agents, Combined/*ADVERSE EFFECTS/THERAPEUTIC USE
AIDS-Related Opportunistic Infections/ETIOLOGY/MORTALITY
Bleomycins/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS Follow-Up Studies
Human Neoplasms, Second Primary/DRUG THERAPY/MORTALITY Sarcoma,
Kaposi's/*DRUG THERAPY/MORTALITY Skin Neoplasms/*DRUG THERAPY/MORTALITY
Survival Rate Treatment Outcome MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).